The Antibacterial Effects of Biphasic Brookite-Anatase Titanium Dioxide Nanoparticles on Multiple-Drug-Resistant Staphylococcus aureus
Abstract:Staphylococcus aureus (S. aureus) acquires resistance to antimicrobial agents shortly after exposure. In spite of the various antibiotics used to treat infections, antimicrobial resistance is an unavoidable consequence. Thus, other prevention modalities are warranted to prevent multiple-drug-resistant (MDR) S. aureus transmission. Titanium dioxide (TiO2) nanoparticles decompose organic compounds by the formation of hydroxyl radicals and superoxide ions when exposed to ultraviolet (UV) light. Commercially available anatase phase TiO2 nanoparticles can serve as antimicrobial agents via UV light activation. However, biphasic brookite-anatase nanoparticles, due to their smaller particle size, may increase the efficiency of TiO2 nanoparticles to inhibit bacterial growth by promoting a greater surface area contact ratio. Both the TiO2 free-suspension and drop-coated slide bioassays were conducted to determine the effects of UV light activated TiO2 nanoparticles on S. aureus and the results revealed non-selective killing properties of the nanoparticles. Furthermore, UV light activated biphasic brookite-anatase nanoparticles (1 mg/mL) caused at least a 7-log reduction in MDR S. aureus cell viability within 30 minutes while anatase nanoparticles, under the same conditions, required approximately 75 minutes for complete cell death. Physical damage to the cells by UV light activated TiO2 nanoparticles was also confirmed by scanning electron microscopy.
Document Type: Research Article
Publication date: 2008-09-01
More about this publication?
- Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites